Market Survey on Acute Migraine Treatment Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Acute Migraine Treatment Market including Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Triptans, Dihydroergotamine, Nonspecific Migraine Medications, and Analgesics Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
The global acute migraine treatment market size is projected to be valued at US$ 8.6 Billion in 2032 and exhibit a CAGR of 4.9% in the forecast period from 2022 to 2032. It is anticipated to reach US$ 2.4 Billion in 2022. The rising prevalence of migraine owing to the rapid adoption of unhealthy lifestyles is anticipated to boost the demand for acute migraine treatment options in the near future.
Report Attribute
Details
Acute Migraine Treatment Market Estimated Base Year Value (2021)
US$ 1.8 Billion
Acute Migraine Treatment Market Expected Market Value (2022)
US$ 2.4 Billion
Acute Migraine Treatment Market Anticipated Forecast Value (2032)
US$ 8.6 Billion
Acute Migraine Treatment Market Projected Growth Rate (2022 to 2032)
4.9% CAGR
Migraine is considered to be a primary headache disorder that is often characterized by recurrent attacks. Ergot alkaloids, nonsteroidal anti-inflammatory drugs, combination analgesics, triptans, and acetaminophen are some of the commonly used drugs for the treatment of migraine.
The treatment of acute migraine is a challenging task owing to the difficulty in predicting individual response to a specific dose or substantial rates of nonresponse to medicines. After the onset of symptoms, abortive therapy is mainly used as soon as possible for treating the condition.
Opioids are usually prescribed for acute migraines in the Emergency Department (ED) despite published guidelines suggesting non-opioid treatments for the same. In addition to that, subcutaneous sumatriptan, prochlorperazine, and intravenous metoclopramide are given to adults suffering from acute migraine.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Which are Some Prominent Drivers Spearheading Acute Migraine Treatment Market Growth
The surging demand for high-quality drugs and increasing awareness among people regarding the treatment and prevention of migraine are projected to bolster the sales of acute migraine treatment options. The rising consumption of alcohol, increasing smoking habits, and surging work pressure are some of the other factors that are anticipated to augur well for the global market.
As per the 2019 National Survey on Drug Use and Health (NSDUH), around 85.6% of people between the age group of 18 years and above reported that they drank alcohol at some point in their life, while nearly 69.5% mentioned that they consumed alcohol in the past year. These numbers are expected to grow at a fast pace in the upcoming years, thereby driving growth in this market.
What are the Challenges Faced by the Acute Migraine Treatment Industry
As the majority of the drugs are still under development, only a handful of them is available for consumption. Various side effects associated with the available drugs, such as dizziness, shortness of breath, nausea, and chest pressure may hinder the global acute migraine treatment market growth in future years.
Find your sweet spots for generating winning opportunities in this market.
Why is North America Emerging as an Opportunistic Acute Migraine Treatment Market
North America is projected to lead in terms of the acute migraine treatment market share in the evaluation period. The rising investment by key players based in the USA and Canada in exhaustive research and development activities to find out new treatment options is estimated to bode well for the regional market.
According to the American Family Physician, nearly 44.5 million adults, including 6% to 9% of men and 18% to 26% of women in the USA suffered from a migraine in 2009. The annual direct costs for migraine surpass US$ 17 billion in the country. This trend is projected to continue throughout the forecast period, thereby propelling the North American market.
How is Asia Pacific Contributing to Growth of the Acute Migraine Treatment Market
The rising healthcare expenditure and the ongoing development of the healthcare infrastructure in emerging countries, such as China and India are anticipated to spur the Asia Pacific acute migraine treatment market size. The easy availability of cost-effective treatment options for migraine backed by rising initiatives by regulatory bodies is another vital factor that is likely to accelerate the regional market.
As per the India Brand Equity Foundation (IBEF), the Indian healthcare infrastructure is estimated to be valued at US$ 349.1 billion by FY22. The penetration of health insurance is likely to expand in this country owing to the increasing demand for quality and affordable healthcare. This factor is set to boost growth across the Asia Pacific.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Market Competition
Some of the prominent companies present in the global acute migraine treatment market are Teva Pharmaceutical, Hoffmann-La Roche Ltd., Johnson and Johnson, Amgen, AstraZeneca, Pfizer Inc., Merck & Co., Novartis AG, and Eli Lilly and Company among others.
Leading vendors operating in the global market are increasingly focusing on broadening their geographic footprint across emerging regions, such as the Middle East, Asia Pacific, and Latin America. Meanwhile, a few other key players are engaging in mergers and acquisitions with start-up companies to strengthen their positions in the global market.
Scope of Report
Report Attribute
Details
Growth Rate
CAGR of 4.9% from 2022 to 2032
Base Year for Estimation
2021
Historical Data
2015 to 2020
Forecast Period
2022 to 2032
Quantitative Units
Revenue in USD Billion, Volume in Kilotons, and CAGR from 2022 to 2032
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug Type
Distribution Channel
Region
Regions Covered
North America
Latin America
Western Europe
Eastern Europe
Asia Pacific Excluding Japan
Japan
Middle East and Africa
Key Countries Profiled
USA
Canada
Brazil
Argentina
Germany
United Kingdom
France
Spain
Italy
Nordics
BENELUX
Australia & New Zealand
China
India
ASIAN
GCC Countries
South Africa
Key Companies Profiled
Teva Pharmaceutical
Hoffmann-La Roche Ltd.
Johnson and Johnson
Amgen
AstraZeneca
Pfizer Inc.
Merck & Co.
Novartis AG
Eli Lilly and Company
Customization
Available Upon Request
Key Segments Profiled in the Acute Migraine Treatment Industry Survey
By Drug Type:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Triptans
Dihydroergotamine
Nonspecific Migraine Medications
Analgesics
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Drug Stores
E-Commerce
By Region:
North America
Latin America
Western Europe
Eastern Europe
Asia Pacific Excluding Japan
Japan
Middle East and Africa
Frequently Asked Questions
The global acute migraine treatment market is anticipated to surpass US$ 8.6 Billion in 2032.
North America is set to lead the acute migraine treatment market in the forecast period.
Teva Pharmaceutical, Hoffmann-La Roche Ltd., Johnson and Johnson, Amgen, AstraZeneca, Pfizer Inc., Merck & Co., and Novartis AG are some of the renowned companies in the acute migraine treatment market.
Table of Content
1. Executive Summary | Acute Migraine Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2022 to 2032
5.3.1. Analgesics
5.3.2. Ergot Alkaloids (Dihydroergotamine)
5.3.3. Triptans
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Drug Type, 2022 to 2032 Deep-dive segmentation will be available in the sample on request
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032
6.3.1. Oral
6.3.2. Intranasal
6.3.3. Intramuscular
6.3.4. Intravenous
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022 to 2032 Deep-dive segmentation will be available in the sample on request
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Specialty Pharmacies
7.3.4. Mail Order Pharmacy
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032 Deep-dive segmentation will be available in the sample on request
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Mexico
10.2.1.2. Brazil
10.2.1.3. Rest of Latin America
10.2.2. By Drug Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. United Kingdom
11.2.1.5. Spain
11.2.1.6. BENELUX
11.2.1.7. Russia
11.2.1.8. Rest of Europe
11.2.2. By Drug Type
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Drug Type
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. South Asia & Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. ASEAN
13.2.1.3. Australia and New Zealand
13.2.1.4. Rest of South Asia & Pacific
13.2.2. By Drug Type
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. Turkey
14.2.1.3. South Africa
14.2.1.4. Rest of Middle East and Africa
14.2.2. By Drug Type
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Drug Type
15.1.2.2. By Route of Administration
15.1.2.3. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Drug Type
15.2.2.2. By Route of Administration
15.2.2.3. By Distribution Channel
15.3. Mexico
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Drug Type
15.3.2.2. By Route of Administration
15.3.2.3. By Distribution Channel
15.4. Brazil
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Drug Type
15.4.2.2. By Route of Administration
15.4.2.3. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Drug Type
15.5.2.2. By Route of Administration
15.5.2.3. By Distribution Channel
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Drug Type
15.6.2.2. By Route of Administration
15.6.2.3. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Drug Type
15.7.2.2. By Route of Administration
15.7.2.3. By Distribution Channel
15.8. United Kingdom
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Drug Type
15.8.2.2. By Route of Administration
15.8.2.3. By Distribution Channel
15.9. Spain
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Drug Type
15.9.2.2. By Route of Administration
15.9.2.3. By Distribution Channel
15.10. BENELUX
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Drug Type
15.10.2.2. By Route of Administration
15.10.2.3. By Distribution Channel
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Drug Type
15.11.2.2. By Route of Administration
15.11.2.3. By Distribution Channel
15.12. China
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Drug Type
15.12.2.2. By Route of Administration
15.12.2.3. By Distribution Channel
15.13. Japan
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Drug Type
15.13.2.2. By Route of Administration
15.13.2.3. By Distribution Channel
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Drug Type
15.14.2.2. By Route of Administration
15.14.2.3. By Distribution Channel
15.15. India
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Drug Type
15.15.2.2. By Route of Administration
15.15.2.3. By Distribution Channel
15.16. ASIAN
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Drug Type
15.16.2.2. By Route of Administration
15.16.2.3. By Distribution Channel
15.17. Australia and New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Drug Type
15.17.2.2. By Route of Administration
15.17.2.3. By Distribution Channel
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Drug Type
15.18.2.2. By Route of Administration
15.18.2.3. By Distribution Channel
15.19. Turkey
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Drug Type
15.19.2.2. By Route of Administration
15.19.2.3. By Distribution Channel
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Drug Type
15.20.2.2. By Route of Administration
15.20.2.3. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Type
16.3.3. By Route of Administration
16.3.4. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Novartis International AG
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Janssen Pharmaceuticals, Inc
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Pfizer Inc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Zydus Cadila
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Abbott
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Sun Pharmaceutical Industries Ltd
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Dr. Reddy's Laboratories Ltd
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Micro Labs Ltd
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Glaxo SmithKline Pharmaceuticals Ltd
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Piramal Healthcare Limited
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. Sanofi S.A.
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
17.1.12. Hetero Drugs Ltd
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.12.5.2. Product Strategy
17.1.12.5.3. Channel Strategy
17.1.13. Lupin Ltd
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.13.5.2. Product Strategy
17.1.13.5.3. Channel Strategy
17.1.14. Alkem Laboratories Ltd
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.14.5.2. Product Strategy
17.1.14.5.3. Channel Strategy
17.1.15. Apex Laboratories Pvt Ltd
17.1.15.1. Overview
17.1.15.2. Product Portfolio
17.1.15.3. Profitability by Market Segments
17.1.15.4. Sales Footprint
17.1.15.5. Strategy Overview
17.1.15.5.1. Marketing Strategy
17.1.15.5.2. Product Strategy
17.1.15.5.3. Channel Strategy
17.1.16. Intas Pharmaceuticals Ltd
17.1.16.1. Overview
17.1.16.2. Product Portfolio
17.1.16.3. Profitability by Market Segments
17.1.16.4. Sales Footprint
17.1.16.5. Strategy Overview
17.1.16.5.1. Marketing Strategy
17.1.16.5.2. Product Strategy
17.1.16.5.3. Channel Strategy
17.1.17. Cipla Ltd
17.1.17.1. Overview
17.1.17.2. Product Portfolio
17.1.17.3. Profitability by Market Segments
17.1.17.4. Sales Footprint
17.1.17.5. Strategy Overview
17.1.17.5.1. Marketing Strategy
17.1.17.5.2. Product Strategy
17.1.17.5.3. Channel Strategy
17.1.18. Healing Pharma
17.1.18.1. Overview
17.1.18.2. Product Portfolio
17.1.18.3. Profitability by Market Segments
17.1.18.4. Sales Footprint
17.1.18.5. Strategy Overview
17.1.18.5.1. Marketing Strategy
17.1.18.5.2. Product Strategy
17.1.18.5.3. Channel Strategy
17.1.19. Torrent Pharmaceuticals Ltd
17.1.19.1. Overview
17.1.19.2. Product Portfolio
17.1.19.3. Profitability by Market Segments
17.1.19.4. Sales Footprint
17.1.19.5. Strategy Overview
17.1.19.5.1. Marketing Strategy
17.1.19.5.2. Product Strategy
17.1.19.5.3. Channel Strategy
17.1.20. Alembic Pharmaceuticals Ltd
17.1.20.1. Overview
17.1.20.2. Product Portfolio
17.1.20.3. Profitability by Market Segments
17.1.20.4. Sales Footprint
17.1.20.5. Strategy Overview
17.1.20.5.1. Marketing Strategy
17.1.20.5.2. Product Strategy
17.1.20.5.3. Channel Strategy
18. Assumptions & Acronyms Used19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032
Table 2: Global Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032
Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 5: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 6: North America Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032
Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 10: Latin America Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032
Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 14: Europe Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032
Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 17: East Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 18: East Asia Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032
Table 19: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 20: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 21: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 22: South Asia & Pacific Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032
Table 23: South Asia & Pacific Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 24: South Asia & Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 25: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 26: MEA Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032
Table 27: MEA Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 28: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Type, 2022 to 2032
Figure 2: Global Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 4: Global Market Value (US$ Million) by Region, 2022 to 2032
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
Figure 8: Global Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032
Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 17: Global Market Attractiveness by Drug Type, 2022 to 2032
Figure 18: Global Market Attractiveness by Route of Administration, 2022 to 2032
Figure 19: Global Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 20: Global Market Attractiveness by Region, 2022 to 2032
Figure 21: North America Market Value (US$ Million) by Drug Type, 2022 to 2032
Figure 22: North America Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 24: North America Market Value (US$ Million) by Country, 2022 to 2032
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 28: North America Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032
Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 37: North America Market Attractiveness by Drug Type, 2022 to 2032
Figure 38: North America Market Attractiveness by Route of Administration, 2022 to 2032
Figure 39: North America Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 40: North America Market Attractiveness by Country, 2022 to 2032
Figure 41: Latin America Market Value (US$ Million) by Drug Type, 2022 to 2032
Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 44: Latin America Market Value (US$ Million) by Country, 2022 to 2032
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032
Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 57: Latin America Market Attractiveness by Drug Type, 2022 to 2032
Figure 58: Latin America Market Attractiveness by Route of Administration, 2022 to 2032
Figure 59: Latin America Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 60: Latin America Market Attractiveness by Country, 2022 to 2032
Figure 61: Europe Market Value (US$ Million) by Drug Type, 2022 to 2032
Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 64: Europe Market Value (US$ Million) by Country, 2022 to 2032
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 68: Europe Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032
Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032
Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 77: Europe Market Attractiveness by Drug Type, 2022 to 2032
Figure 78: Europe Market Attractiveness by Route of Administration, 2022 to 2032
Figure 79: Europe Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 80: Europe Market Attractiveness by Country, 2022 to 2032
Figure 81: East Asia Market Value (US$ Million) by Drug Type, 2022 to 2032
Figure 82: East Asia Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 83: East Asia Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 84: East Asia Market Value (US$ Million) by Country, 2022 to 2032
Figure 85: East Asia Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 86: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 88: East Asia Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032
Figure 89: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032
Figure 90: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032
Figure 91: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 92: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 93: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 94: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 95: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 97: East Asia Market Attractiveness by Drug Type, 2022 to 2032
Figure 98: East Asia Market Attractiveness by Route of Administration, 2022 to 2032
Figure 99: East Asia Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 100: East Asia Market Attractiveness by Country, 2022 to 2032
Figure 101: South Asia & Pacific Market Value (US$ Million) by Drug Type, 2022 to 2032
Figure 102: South Asia & Pacific Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 103: South Asia & Pacific Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 104: South Asia & Pacific Market Value (US$ Million) by Country, 2022 to 2032
Figure 105: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 106: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 107: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 108: South Asia & Pacific Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032
Figure 109: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032
Figure 110: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032
Figure 111: South Asia & Pacific Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 112: South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 113: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 114: South Asia & Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 115: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 116: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 117: South Asia & Pacific Market Attractiveness by Drug Type, 2022 to 2032
Figure 118: South Asia & Pacific Market Attractiveness by Route of Administration, 2022 to 2032
Figure 119: South Asia & Pacific Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 120: South Asia & Pacific Market Attractiveness by Country, 2022 to 2032
Figure 121: MEA Market Value (US$ Million) by Drug Type, 2022 to 2032
Figure 122: MEA Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 123: MEA Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 124: MEA Market Value (US$ Million) by Country, 2022 to 2032
Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 128: MEA Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032
Figure 129: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032
Figure 130: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032
Figure 131: MEA Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 132: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 134: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 135: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 136: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 137: MEA Market Attractiveness by Drug Type, 2022 to 2032
Figure 138: MEA Market Attractiveness by Route of Administration, 2022 to 2032
Figure 139: MEA Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 140: MEA Market Attractiveness by Country, 2022 to 2032
